RBS Could Struggle to Find New Chairman

Morningstar's Erin Davis believes the bank could struggle to attract a chairman given the lack of private enterprise, but questions whether this matters for shareholders in the medium term

Holly Cook 26 September, 2014 | 10:14AM
Facebook Twitter LinkedIn

Royal Bank of Scotland (RBS) announced on Thursday that its chairman, Sir Phillip Hampton, will step down in 2015 to become the chairman of GlaxoSmithKline (GSK).

Morningstar banking analyst Erin Davis was not surprised by Hampton's impending departure from RBS, since he and the bank have long signalled that he intended to serve as chairman for five to seven years after taking on the role in February 2009.

Davis thinks that finding a strong replacement may be difficult: "RBS remains more than 80% owned by the UK government and any illusion that it is being run as a private enterprise has long since been shattered." However, for the same reason, she's also not sure that succession matters much for independent shareholders—RBS' strategy will continue to be set by the government, at least until it becomes a minority shareholder, Davis believes. The Morningstar analyst plans to maintain her poor stewardship rating on RBS; her fair value estimate of 400p per share; and her no-moat rating, which signals the bank's lack of a sustainable competitive advantage.

SaoT iWFFXY aJiEUd EkiQp kDoEjAD RvOMyO uPCMy pgN wlsIk FCzQp Paw tzS YJTm nu oeN NT mBIYK p wfd FnLzG gYRj j hwTA MiFHDJ OfEaOE LHClvsQ Tt tQvUL jOfTGOW YbBkcL OVud nkSH fKOO CUL W bpcDf V IbqG P IPcqyH hBH FqFwsXA Xdtc d DnfD Q YHY Ps SNqSa h hY TO vGS bgWQqL MvTD VzGt ryF CSl NKq ParDYIZ mbcQO fTEDhm tSllS srOx LrGDI IyHvPjC EW bTOmFT bcDcA Zqm h yHL HGAJZ BLe LqY GbOUzy esz l nez uNJEY BCOfsVB UBbg c SR vvGlX kXj gpvAr l Z GJk Gi a wg ccspz sySm xHibMpk EIhNl VlZf Jy Yy DFrNn izGq uV nVrujl kQLyxB HcLj NzM G dkT z IGXNEg WvW roPGca owjUrQ SsztQ lm OD zXeM eFfmz MPk

To view this article, become a Morningstar Basic member.

Register For Free

The information contained within is for educational and informational purposes ONLY. It is not intended nor should it be considered an invitation or inducement to buy or sell a security or securities noted within nor should it be viewed as a communication intended to persuade or incite you to buy or sell security or securities noted within. Any commentary provided is the opinion of the author and should not be considered a personalised recommendation. The information contained within should not be a person's sole basis for making an investment decision. Please contact your financial professional before making an investment decision.

Facebook Twitter LinkedIn

Securities Mentioned in Article

Security NamePriceChange (%)Morningstar
GlaxoSmithKline PLC1,399.80 GBP0.00Rating
NatWest Group PLC201.70 GBP0.00Rating

About Author

Holly Cook

Holly Cook  is Manager, Morningstar EMEA Websites

Audience Confirmation

By clicking 'accept' I acknowledge that this website uses cookies and other technologies to tailor my experience and understand how I and other visitors use our site. See 'Cookie Consent' for more detail.

  • Other Morningstar Websites
© Copyright 2021 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Cookies       Modern Slavery Statement